INSM
- Insmed Incorporated
()
Overview
Company Summary
Insmed Incorporated (INSM) is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare diseases with unmet medical needs. They are dedicated to transforming the lives of patients suffering from severe and debilitating diseases for which there are limited or no treatment options.
Insmed's primary area of expertise lies in respiratory diseases, specifically non-tuberculous mycobacterial (NTM) lung infections and rare lung diseases. NTM lung infections are caused by mycobacteria other than tuberculosis and can be challenging to diagnose and treat effectively. Insmed is dedicated to providing innovative treatment options and improving the quality of life for patients battling these infections.
The company's flagship product is ARIKAYCE� (amikacin liposome inhalation suspension), which is the first and only FDA-approved treatment for NTM lung infections caused by Mycobacterium avium complex (MAC). ARIKAYCE is an inhalable antibiotic delivered directly to the lungs, helping to combat the infection and reduce its impact on patients.
Insmed also focuses on developing therapies for rare lung diseases, such as pulmonary non-tuberculous mycobacterial disease, cystic fibrosis, and bronchiectasis. They invest in research and development to identify new treatment options and leverage their expertise in respiratory diseases to address these unmet medical needs.
In addition to their dedication to developing novel therapies, Insmed is also engaged in various clinical trials and collaborations to expand their pipeline and explore potential treatments for other rare diseases.
Overall, Insmed Incorporated is committed to addressing the significant unmet medical needs of patients with rare respiratory diseases through innovative research, development, and commercialization of therapeutics like ARIKAYCE.